Neoplasms

Blood and Lymph Conditions

All Conditions

Immune System Diseases

Symptoms and General Pathology

Rare Diseases

Leukemia

Leukemia, Lymphoid

Leukemia, Lymphocytic, Chronic, B-Cell

Neoplasms by Histologic Type

Hematologic Diseases

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Leukemia, B-Cell

Chronic Disease

Disease Attributes

Chronic Graft Versus Host Disease

Chronic Lymphocytic Leukemia

Anti-Infective Agents

Pharmaceutical Solutions

All Drugs and Chemicals

Herbal and Botanical

Phenol

Olive

Patients with CLL consumed before their meals, 40 ml/day of EVOO rich in oleocanthal and oleacin for 6 months,

Patient's history were recorded for third and sixth month before dietary the intervention, taking into consideration that the patients did'nt consume high phenolic EVOO.

During the pilot dietary intervention patients with CLL consumed before their meals, 40 ml/day high phenolic EVOO for 6 months

High phenolic EVOO intake

Medical record of each patient's was followed during 6 month before dietary the intervention

No High phenolic EVOO intake

Prokopios Magiatis, PhD

Daily intake of extra virgin olive oil (EVOO), which is the major component of the Mediterranean diet and also a source of monounsaturated fat, may be partly responsible for the increased life expectancy of the Mediterranean people. A high dietary intake of EVOO is correlated with lower incidence of cancer, cardiovascular disease, metabolic diseases, Alzheimer's disease and osteoporosis Oleocanthal, a phenolic derivative of extra virgin olive oil, has important health promoting anti-cancerous properties, since it can inhibit the growth and promote the apoptosis of several cancer cells.

The purpose of the present study was to investigate the effect of dietary intake of olive oil rich in oleocanthal on hematological, metabolical, cell progression markers and disease progression in patients with Chronic Lymphocytic Leukemia. The aim is also to study the possible association of apoptosis in the mechanism of action of virgin olive oil phenols in a patient with CLL in order to find the possible mechanism of the cellular action of oleocanthal in neoplasia.

After the screening of \>300 EVOO samples the investigators selected an EVOO with high oleocanthal and oleacin concentration of 416 and 284 mg/Kg respectively (EVOO OC/OL). Pilot dietary intervention was made in a group of 21 patients with chronic lymphocytic leukemia (CLL) who did not follow any treatment. EVOO was administered 40 ml/day for six months. Biochemical, hematological and molecular markers were studied six month before the intervention and six month during the intervention

Extra virgin olive oil (EVOO) is the major component of the Mediterranean diet. More than 200 different chemical compounds have been detected in olive oil, including fatty acids, sterols, carotenoids, terpenoids, flavonoids, tocopherols and olive polyphenols. Virgin olive oil contains a variety of important phenolic components, mainly corresponding to the compounds tyrosol, hydroxytyrosol, oleocanthal (OC) ,oleacin (OL) ,ligstroside and oleuropein aglycones .Among these olive phenols, oleocanthal , a dialdehydic form of dicarboxymethyl ligstroside aglycone which has been isolated from EVOO, presents a wide range of biological effects including antioxidant, anti-inflammatory, anticancer, neuroprotective and antidiabetic activities and for this reason has attracted more scientific attention.

Chronic Lymphocytic Leukemia (CLL), the most commonly diagnosed adult leukemia in Western countries, is responsible for about 1 in 4 cases of all leukemias. It is characterized by the accumulation of monoclonal B-cells in bone marrow, peripheral blood, lymphatic tissues and spleen, while it is often asymptomatic and slow in its development. Patients with CLL do not always require immediate therapy. However, patients who appear symptoms have an approximate median survival range from 18 months to 6 years depending on the clinical stage. Criteria for the diagnosis of CLL are monoclonal B lymphocytes ≥5000 lymphocytes/ml in the peripheral blood for at least 3 months, prolymphocytes ≤55%, co-expression of claster of diferentiation (CD)5 and B-cell surface antigens CD 19, CD 20, and CD 23, low levels of CD 20, CD 79b and low expression of surface immunoglobulins (sIg), and kappa or lambda light chain restriction. The standard clinical procedures to estimate prognosis are the clinical staging systems developed by Rai et al and Binet et al.

The level of apoptosis in hematopoiesis may provide information about the mechanism which is responsible for the regulation of progenitor's and stem cell's proliferation. The dysfunction of apoptosis has found to be associated with leukemia. An increase in the expression of Apo-1/fas (CD 95) apoptotic marker in myeloid progenitor cells in CLL patients and a corresponding decrease in the apoptotic B-cell lymphoma 2 (BCL-2) inhibitor has been described. Recent studies showed also that the increase in CLL patients' lymphocytes may be due to the disturbed balance between the proliferation and apoptosis of CLL cells while the changes in apoptosis-related protein expression are recognized during all the stages of Binet in CLL. The p38 levels are reduced (resistance to apoptosis) and Induced myeloid leukemia cell differentiation protein (Mcl-1) and Survivin levels are elevated, so as to enhance the survival of B lymphocytes.

Survivin is a protein inhibitor of apoptosis which inhibits caspases and blocks cell death. It is highly expressed in most cancers, including hematological, and is associated with a poor clinical outcome. The apoptotic marker CD 95 (Apo-1/fas) and its ligand, CD 95 is a death receptor ligand that mediates apoptosis induction in order to maintain immune homeostasis and has the capacity to mediate apoptosis induction in cancer cells, generating an 18-kilodalton fragment termed caspase-cleaved cytokeratin-18 (cCK-18).

Oleocanthal has been shown to induce cytotoxicity and apoptosis in vitro in human acute promyelocytic leukemia and in myeloma cells. It may also cause primary necrosis and cellular apoptosis by inducing lysosomal membrane permeability in different cancer cell lines.

The aim of this study taking into account the strong apoptotic properties of oleocanthal in vitro, was to investigate its ability, under real clinical settings, to affect the hematological and biochemical profile; also the cellular apoptotic markers Survivin, cCK18- (caspase activity marker) and Apo1fas/CD 95 in CLL patients after taking into consideration the progression of their disease. For this reason was conducted a dietary intervention study comparing the antineoplastic effects of an oleocanthal-rich EVOO in CLL patients.

Material and Methods

In the current study, a screening of 300 commercial samples (selected among a database of \>3000 samples), obtained from olives (Olea europaea L.) harvested in 2017-2018 season, was performed by the Quantitative NMR spectroscopy (qNMR) method in order to identify oils which could fulfill the following criteria: The extravirgin oil would have high oleocanthal and oleacin content (D1 index) and low or even no content in other secoiridoid conjugated phenolics (3-8) or free tyrosol and hydroxytyrosol Specifically Oil rich in Oleocanthal was obtained from Monovarietal oil of Lianolia Kerkyras variety provided by "The Governor" Company from Agios Matthaios, Corfu, Greece. This oil contained: Oleocanthal 416±7 mg/Kg, oleacin 284±10 mg/Kg, Tyrosol \< 10 mg/Kg, Hydroxytyrosol \< 10 mg/Kg (D1 = 700 mg/Kg). It should be mentioned that apart the qNMR analysis, the hydroxytyrosol and tyrosol content was also measured by the standard IOC method for measurement of olive oil biophenols. Selected EVOO immediately after their analysis and until the beginning of the study period were stored at 4 celsious degree in order to minimize possible alterations in chemical composition.

Subjects Twenty one patients from the hematologic clinic of the General hospital of Lakonia (Greece), were enrolled to participate in the dietary intervention. CLL diagnosis was confirmed by standard criteria. Patients were untreated, in Rai stage 0 to II.

Dietary Intervention At the begin of the pilot study medical exams of each patient's history were recorded for third and sixth month before dietary the intervention. The clinical record before the dietary intervention concerns the hematological profile, biochemical exams including, lipidemic profile, fasting glucose, Liver and kidney function markers, as well as data concerning blood marrow biopsy, neoplastic markers and immunophenotype. Drug treatment or comorbidities were also recorded.

At the begin of the pilot dietary intervention a group of 21 patients with CLL consumed before their meals, 40 ml/day of EVOO rich in olecanthal and oleacin (OC/OL) for 6 months, in order to explore the effect of the dietary consumption of the A-EVOO on the studied hematological, biochemical and molecular markers. The amount of the consumed EVOO OC/OL was chosen according to a previous study. (15) Patients were advised to continue their regular diet; their adherence to the study protocol was assessed by two 24-h telephone recalls every two weeks.

Peripheral blood samples from the 21 patients with CLL were gathered at the begin, after 3 months and after 6 months from the begin of the dietary intervention. Whole blood count and complete biochemical tests were performed for fasting glucose, blood lipid profile, and markers of liver and kidney function. Serum analyses were conducted using the same procedure and at the same lab with the use of a biochemical analyzer (Olympus AU-600, Olympus, Tokyo, Japan).

A commercially available enzyme-linked immunosorbent assay (ELISA) was used according to the instructions of the supplier to assay the apoptotic markers M30 Apoptosense-cCK18 (VLVbio Hästholmsvägen, Sweden), Apo-1/Fas/CD 95 (Novus Biologicals, Colorado USA) and the antiapoptotic marker Survivin (OriGene Technologies, Inc USA) into plasma samples of all the patients at all the studied time points.

Statistical analysis was performed using SPSS v.24 (SPSS Inc., Chicago, IL. USA) and the significance level was set at 0.05. Initially a descriptive analysis of the sample was performed in terms of age, sex, clinical, biochemical and molecular markers. The markers were found to be skewed at p \< 0.05 significance level when checked by using the Kolmogorov-Smirnov test. Therefore non-parametric Mann-Whitney U test were used to find out the differences between the intervention and the control group.

The differences between the time intervals of the intervention was assessed with Friedman non-parametric test followed by Dunn's test for multiple comparison Finally, the correlations of the molecular markers with the clinical parameters included in the study and were checked with Spearman Rho.

Twenty one patients with Chronic lymphocytic leukemia (CLL) from the hematologic clinic of the General hospital of LaKonia (Greece), were enrolled to participate in the dietary intervention. CLL diagnosis was confirmed by standard criteria. Patients were untreated, in Rai stage 0 to II, did not met criteria to initiate chemotherapy and had no neoplasmatic comorbidity. Subjects were randomly selected from the Hematology Department of the General Hospital of Lakonia. Exclusion criteria were neoplastic comorbidities or severe metabolic diseases. Only one group participates in this study, which performed dietary intervention consuming EVOO rich in oleocanthal and oleacin. Clinical and molecular markers were registered 6 months before the intervention and 6 months during the intervention.

Dietary Intervention With High Phenolic EVOO in CLL

Effect of Dietary Intervention With High-Oleocanthal and Oleacin Extra Virgin Olive Oil in Patients With Chronic Lymphocytic Leukemia a Pilot Study

There is not a plan to make Individual participant data (IPD) available.

The effect of the dietary intake of high phenolic EVOO on hematologic profile was investigated comparing the complete blood count before (6 and 3 months) at the starting point of the dietary intervention and during (3 and 6 months) the dietary intervention in order to evaluate possible sustained hematologic improvement according to Rai et al criteria. Whole cell blood account was evaluated by hematological analyzer.

The effect of the dietary intake of high phenolic EVOO on apoptotic markers was investigated comparing the protein expression level on serum of the participants by ELISA. The apoptotic proteins Apo-1/Fas CD 95 (pg/ml) and CCK18 (U/L) and the antiapoptotic protein Survivin (pg/ml) were studied. The mentioned markers were evaluated at the starting point of the intervention, at 3 and 6 months during the dietary intervention with high phenolic EVOO in order to evaluate the in vivo the effect of high phenolic EVOO on protein expression of the studied apoptotic markers in CLL.

The effect of the dietary intake of high phenolic EVOO on fasting glucose (mg/dL), was investigated comparing the fasting glucose before the intervention (6 and 3 months) at the starting point of the intervention, at 3 and 6 months during the dietary intervention with high phenolic EVOO. The correlation of the changes on the fasting glucose during the survey with the hematological outcome of the patient with CLL was also investigated.

The effect of the dietary intake of high phenolic EVOO on lipidemic profile (cholesterol (mg/dl), Low density lipoprotein (LDL- mg/dl), Hight density lipoprotein (HDL mg/dl), tryglicerides (mg/dl) was investigated comparing the lipidemic profile before the intervention (6 and 3 months) at the starting point of the intervention, at 3 and 6 months during the dietary intervention with high phenolic EVOO. The correlation of the changes on the lipidemic profile during the survey with the clinical outcome of the patient with CLL was also investigated.

The effect of the dietary intake of high phenolic EVOO on liver function was investigated comparing the biochemical markers of the liver function (Serum glutamic pyruvic transaminase (SGPT (U/L)), Serum glutamic oxaloacetic transaminase (SGOT(U/L) ), lactate dehydrogenase (LDH(U/L)), alkaline phosphatase (ALP(U/L)), gamma-glutamyl transferase (γ-GT(U/L) before the intervention (6 and 3 months) at the starting point of the intervention, at 3 and 6 months during the dietary intervention with high phenolic EVOO. The correlation of the changes on the liver function during the survey with the clinical outcome of the patient with CLL was also investigated.

The effect of the dietary intake of high phenolic EVOO on kidney function was investigated comparing the conventional biochemical markers of the kidney function Urea(mg/dl) and creatinine (mg/dl ) before the intervention (6 and 3 months) at the starting point of the intervention, at 3 and 6 months during the dietary intervention with high phenolic EVOO. The correlation of the changes on the kidney function during the survey with the clinical outcome of the patient with CLL was also investigated.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Dietary Intervention With High Phenolic EVOO in CLL	NCT04215367	Chronic Lymphoc...	High phenolic E... No High phenoli...	54 Years - 84 Years	University of Peloponnese
Dietary Intervention With High Phenolic EVOO in CLL	NCT04215367	Chronic Lymphoc...	High phenolic E... No High phenoli...	54 Years - 84 Years	University of Peloponnese
Dietary Intervention With High Phenolic EVOO in CLL	NCT04215367	Chronic Lymphoc...	High phenolic E... No High phenoli...	54 Years - 84 Years	University of Peloponnese

Spots Global Cancer Trial Database for phenols

Every month we try and update this database with for phenols cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for phenols

Every month we try and update this database with for phenols cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for phenols cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.